The Federal Trade Commission has signaled once again that ambulatory surgery center (ASC) transactions will receive close antitrust review, even when the parties involved are…
The Federal Trade Commission has signaled once again that ambulatory surgery center (ASC) transactions will receive close antitrust review, even when the parties involved are well-established healthcare operators. In a proposed consent order announced this month, the FTC conditioned Ascension Health Alliance's $3.9 billion acquisition of AmSurg on a substantial divestiture package designed to preserve competition in five concentrated metropolitan markets. The action confirms that the agency views the ASC sector as a meaningful site of competitive activity and will not hesitate to require structural remedies where a transaction threatens to consolidate local outpatient surgical capacity.
Under the proposed order, Ascension must divest seven AmSurg ambulatory surgery centers located in Nashville, Panama City, Tulsa, Waco, and Wichita. Six of those facilities will be transferred to SC Affiliates, while the seventh will be acquired by Florida Gastroenterology Center. The willingness of the FTC to approve a multi-buyer remedy package is notable. It suggests the agency is prepared to accept tailored divestiture solutions involving more than one acquirer, provided that each transaction credibly restores competitive conditions in the affected local market. Parties contemplating remedy proposals in future ASC deals should take note of this flexibility while recognizing that the agency continues to demand buyers with the operational capacity to maintain meaningful competition.
Perhaps the most significant aspect of the order is the imposition of a ten-year prior notice obligation on Ascension. Before completing any additional ambulatory surgery center acquisitions in the affected metropolitan areas, the company must notify the FTC, extending regulatory oversight well beyond the closing of the AmSurg transaction. Long-tail prior-notice obligations of this kind create ongoing compliance burdens and can materially affect deal planning, timing, and strategic growth in specific geographic markets.
For healthcare systems, physician groups, and private equity sponsors pursuing ASC roll-ups, the Ascension-AmSurg matter underscores the importance of early antitrust diligence, careful market definition analysis, and a realistic assessment of potential divestiture exposure. Transaction structuring should account not only for clearance risk but also for the possibility of multi-year reporting requirements that may constrain future activity in concentrated metropolitan areas.
This article is provided for general informational purposes only. Clients considering a transaction in this sector should seek tailored legal advice addressing their specific circumstances.